Pyridoxamine reduces inflammatory and microcirculatory abnormalities in metabolic dysfunction-associated steatohepatitis and modulates key factors in the hepatic AGE/ALE signaling pathway.

ABSTRACT: Metabolic dysfunction-associated steatohepatitis (MASH) is an increasing public health concern for which new therapies are urgently needed. As growing evidence suggests that the advanced glycation/lipoxidation end products (AGE/ALE) pathway contribute to disease progression, we investigated how pyridoxamine modulates hepatic AGE/ALE-related signaling in a murine model of MASH, as well as its pharmacological impact on key features of MASH. C57BL/6 mice were fed either a standard diet (Control) or a high-fat, high-carbohydrate diet with 2% cholesterol (HFHC + CHOL2%) for 12 weeks. From weeks 6-12, subgroups of both diet groups received pyridoxamine (200 mg/kg/day), while the remaining mice received vehicles. Body and liver weights, blood glucose levels, adipose tissue distribution, liver his

SUBMITTER: Silvares RR 

PROVIDER: S-EPMC12852023 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature